UK Startup Backed by Patrick Collison Exits Stealth to Generate Drug Discovery Data From Physics
The round's core claim is that the AI drug discovery field has not stalled because its models are bad. It has stalled because the data those models train on is finite, biased toward commercially attractive disease targets, and increasingly exhausted.